Cherry-red spot

From EyeWiki
All contributors:
Assigned editor:
Assigned status Update Pending

Cherry red spot is a fundoscopic finding  in the macula observed in central retinal vein occlusion (CRAO) and in a variety of lipid storage disorders.

Disease Entity

Add text here


A cherry-red spot (CRS) at the macula is a clinically significant sign found on fundus examination[1] in a variety of pathological conditions, including lysosomal storage disorders, retinal ischemia, and retinal infarction.[2] The term refers to the appearance of a red-tinted region at the center of macula surrounded by retinal opacification[2] and is a clinical sign usually seen within the context of thickening and loss of transparency in the posterior pole of the retina.[3] The fovea being the thinnest part of the retina and devoid of ganglion cells, retains relative transparency, due to which the color of the choroids shines through.[3] In the case of lipid storage diseases, the lipids are stored in the ganglion cell layer of the retina, giving the retina a white appearance. As ganglion cells are absent at the foveola, this area retains relative transparency and contrasts with the surrounding retina.[3] The appearance of a cherry red spot may also result from retinal edema due to central retinal artery occlusion or traumatic retinal ischemia, which causes the perimacular tissue to appear pale, while the fovea maintains its normal color[4], it receives its blood supply from the choroid, supplied by the long and short posterior ciliary arteries.[5]

A useful sign, when clubbed with key clinical features and a good history, it often guides one to the diagnosis of the disease.[1]

A macular hemorrhage or hole, with resulting enhanced red contrast relative to the surrounding retina, may be confused with a cherry red spot.[4]


The causes of the cherry-red spot in the macula can be categorized into 5 groups, according to etiology:


  • Central retinal artery occlusion (CRAO) - This disease entity characteristically presents as a sudden onset of painless, unilateral visual loss in elderly patients, most commonly caused by an embolism, which blocks the central retinal artery. The embolus may be composed of cholesterol, fibrin-platelet, or calcium and usually originates from the carotid plaque and less commonly from the heart or the aorta. Inflammatory conditions like giant cell arteritis (GCA), may also cause CRAO, though branch retinal arterial occlusion (BRAO) is not a common feature in GCA. Branch retinal arterioles do not have a continuous muscular coat or internal elastic lamina.[1] GCA involves only medium and large size arteries and not arterioles (like branch retinal arteriole). However, GCA might affect the cilioretinal artery, which is a branch of the posterior ciliary artery. On cursory examination, an examiner might mistake cilioretinal arterial occlusion in GCA for a BRAO. Other causes of central retinal artery occlusion include myxoma or vegetations of the cardiac valves, thrombophilic disorders, and retinal migraine. Other associations of CRAO include dyslipidemia, diabetes, hypertension, smoking, and pyoderma gangrenosum.[2] In an extensive series of 248 eyes of 240 patients with central retinal artery occlusion, the cherry-red spot was present on the initial examination in 90% of permanent CRAO cases.[3] Retinal whitening and a cherry-red spot are important manifestations of acute CRAO. Other related situations causing a cherry-red spot include[4]:

Acute occlusion of the choroidal circulation causing outer retinal whitening and a cherry-red spot at the macula following cataract surgery (phacoemulsification)

Intraorbital hemorrhage or mass may compromise the choroidal and retinal circulation and lead to a cherry-red spot at the macula

Leukemic infiltrates of the optic nerve head may cause CRAO and cherry red spot

Optic nerve avulsion may cause a cherry-red spot at the macula

Macular infarction due to various causes

Metabolic Storage Diseases

  • Tay-Sachs disease (GM2 gangliosidosis type 1, infantile amaurotic familial idiocy, B variant GM2 gangliosidosis)- This is the most common type of gangliosidosis due to deficiency of the alpha subunit of hexosaminidase A on chromosome 15q23. The disease has an onset of the symptoms in the infancy. There is an abnormal accumulation of gangliosides in the brain and ganglion cell layer of the retina. The disease is fatal, and most affected children die within the first 2 to 5 years of age. This neurodegenerative disorder is inherited in an autosomal recessive fashion. The child will have a developmental delay. Other features include a cherry-red spot at the macula in both eyes, increased startle response, poor head control, seizures, dementia, apathy, hypotonia, deafness, blindness, and late hypertonia. Incidence is very high in Ashkenazi Jews, at around 1 in 3500 to 4000 births. A cherry-red spot is present in approximately 90% of the patients affected with the disease.

GM2 gangliosidosis type 2 or Sandhoff disease is due to mutation of the beta subunit of hexosaminidase at chromosome 5q13. Reports describe infantile, juvenile, and adults forms. It is inherited autosomal recessively. The cherry-red spot is present in a majority of cases. Clinical features are similar to Tay-Sachs disease. 

Commotio retinae - After blunt trauma, acutely retinal opacification may occur.[5] When this whitening of the retina involves the macula, it is called Berlin's edema. Although actual retinal thickening is not present, this peripheral whitening can cause a pseudo-cherry red spot.

Niemann-Pick disease - Type A and B result from the deficiency of acid sphingomyelinase enzyme, which is a product of the SMPD1 gene (sphingomyelin phosphodiesterase-1) on chromosome 11p15.4. There is an accumulation of sphingomyelin in the tissues. The cause of Niemann-Pick disease type C1 and type D is a mutation in the NPC1 gene on chromosome 18q11. Niemann-Pick disease C2 is due to a mutation in the NPC2 gene at chromosome 14q24.3. Both NPC1 and NPC2 genes are involved in the transport of lipids (LDL cholesterol or low-density lipoprotein cholesterol) in endosomes and lysosomes.

Type A disease (classic infantile) has an early onset and severe neurodegeneration. Hepatosplenomegaly may be present in early infancy, and there may be a failure to thrive and a suboptimal gain of weight. The developmental milestones may be normal until the first birthday, after which there may be psychomotor regression or progressive loss of mental abilities and motor performance. Interstitial lung disease may be noted, and death usually occurs in early childhood. Most of the affected children have a cherry-red spot at the macula.

Type B, usually (visceral), has a normal function of the central nervous system (CNS). Disease onset is usually in the mid-childhood, and presentation is similar to but less severe than type A. Features include short stature, hepatosplenomegaly, recurrent pulmonary infections, and thrombocytopenia. Some patients may have mixed features of type A, and B. Cherry-red spot at the macula is noted in around 1/3rd cases. 

Type C (subacute/juvenile) has a slowly progressive disease and moderate CNS damage. Features include ataxia, speech and swallowing difficulty, vertical supranuclear gaze palsy, dystonia, interstitial lung disease, intellectual decline, and seizures.

Type D (Nova Scotia form noted in individuals from Nova Scotia of Canada who have an Acadian ancestor) is associated with late-onset disease but may lead to severe CNS involvement with time. Currently, it classifies as the same condition as type C.

GM1 gangliosidosis type 1 (Generalized gangliosidosis or Landing disease) results from the deficiency of beta-galactosidase at chromosome 3p22.3. A cherry-red spot in the macula occurs in around 50% cases.[6] There are three variants:

Type I or infantile form is characterized by a severe disease with onset within the first year of life. Facial features are coarse with gingival hypertrophy. Other findings include developmental regression, increased startle response, skeletal anomalies, hepatosplenomegaly, intellectual disability, seizures, a cherry-red spot at the macula, corneal clouding, and death within early childhood.

Type II or the late infantile or juvenile form presents within 18 months or 5 years, respectively. The severity is less than type I and the cherry-red spot at the macula or visceromegaly or facial features like type I is usually not seen.

Type III or adult or chronic form is the mildest form. Features include dystonia and vertebral anomaly. The age of onset and life expectancy may be variable.

  • Sialidosis or mucolipidosis type 1 is a lysosomal storage disease cause by alpha-neuraminidase deficiency and presents with ataxia, movement disorders, nystagmus, and myoclonic seizures. Intellect is usually normal, and somatic features are generally not seen. Two types have been described according to the age of onset and severity of the disease: Sialidosis type I or cherry-red spot myoclonus syndrome is characterized by onset in the 2nd or 3rd decade, gait disturbances, myoclonus, ataxia, tremor, a cherry-red spot at the macula, and seizures. The intellect and life expectancy are usually not affected, though the patient eventually needs wheelchair assistance with time. Almost all the patients have the cherry-red spot at the macula.[7]
  • Farber disease (Farber lipogranulomatosis) is a rare autosomal recessive (AR) disorder characterized by Ceramidase or acid ceramidase (chromosome 8p22) deficiency . The typical triad consists of painful swollen joints, subcutaneous nodules (lipogranulomas), and weak cry or hoarse voice due to laryngeal nodules. Other features include a developmental delay, visceromegaly, respiratory involvement, and neurological features, including quadriplegia, seizures, and myoclonus.
  • Metachromatic leukodystrophy is another rare (AR) lysosomal storage disorder described by arylsulfatase A or deficiency, resulting in abnormal collection of sulfatides in myelin-producing cells that leads to progressive destruction of white matter (leukodystrophy). A cherry-red spot at the macula is occasionally a finding in fundoscopy along with progressive decline in intellectual and motor functions, peripheral neuropathy resulting in diminished sensations, hearing loss, incontinence, loss of speech and mobility, blindness, unresponsiveness, and eventual death.
  • Galactosialidosis (Goldberg Cotlier syndrome or neuraminidase deficiency with beta-galactosidase deficiency or cathepsin A deficiency) is an AR disorder due to a mutation in the CTSA gene (chromosome 20q13.12) coding for cathepsin A. The disease characteristically presents with seizures, mental retardation, growth retardation, dysostosis multiplex, coarse facies, short stature, skin hemangiomas, mitral and atrial valvular disease, and deafness. Ocular features include a cherry-red spot at the macula, corneal clouding, and conjunctival telangiectasia.

Hyperalimentation causing hyperlipidemia

Retinitis involving the central retina- including progressive outer retinal necrosis, subacute sclerosing panencephalitis[8][9][10]

Drug Toxicity

  • Quinine
  • Carbon monoxide
  • Dapsone poisoning associated with hemolytic anemia and peripheral neuropathy
  • Methanol
  • Intravitreal gentamicin

The association between Gaucher disease and the presence of a cherry-red spot in the macula is questionable.

Risk Factors

Add text here

General Pathology

Add text here


The macula is characterized histologically by an area with more than one layer of ganglion cell layers, and the ganglion cell layer is thick at the macula. In diseases causing loss of transparency (whitening or opacification) of the inner retina, the reddish color of the vascular choroid and pigmentation of retinal pigment epithelium (RPE) is not seen through the opacified retina. However, foveola is devoid of the inner retinal layer. The retinal layers present at the foveola are (from inside outwards)- internal limiting membrane, outer nuclear layer, external limiting membrane, photoreceptor layer, and RPE. Inner retinal layers are absent in mature foveola. The vascular supply of the fovea is from the choroid, and in the occlusion of retinal vessels, it does not get hampered. Thus foveola, the thinnest part of the central retina, does not lose its transparency in inner retinal ischemia.

Thus, when there is inner retinal opacification, the reddish color of the vascular choroid and the RPE is still seen through the foveola, which is surrounded by an area of the white/opacified retina; this gives rise to the typical cherry-red spot. The size of the cherry-red spot depends on the size of the foveola.

As the color of choroid and RPE varies with racial variation, the color of foveola or the central dot may change according to race. A true cherry-red spot presents in whites. The color of foveola was brown, causing a cherry brown spot in a Canadian aboriginal child with Sandhoff disease and black in a patient of east Indian race creating a cherry black spot in Sandhoff disease.[13] Thus an alternate name of 'perifoveal white patch' has been suggested.[13]

Therefore for a cherry-red spot to be seen, the vascularity of choroid needs to be intact. In cases of ophthalmic artery occlusion, there is a compromise to the vascular supply to retina, choroid, and optic nerve head circulation. There is retinal opacification without a cherry-red spot and severe vision loss, which might cause no perception of light or inaccurate projection of rays.

Opacification of the inner retina can occur as a result of either retinal ischemia due to occlusion of the central retinal artery - The retinal whitening is typically most prominent in the posterior pole, and the opaque retina obscures the details of the choroidal vessels. The whitening of the retina becomes less prominent a little peripheral to the arcades, which may be related to the reduced inner retinal thickness at the peripheral retina. There is a cessation of axoplasmic transport and then the opacification of both the ganglion cell and the nerve fiber layer in a CRAO.

or deposition / accumulation of material at the level of the ganglion cell layer - In Tay-Sachs disease and other lipid storage disorders (sphingolipidoses), there is a progressive abnormal excessive intracellular accumulation of various glycolipids/phospholipids in the ganglion cell layer leading to opacification of the inner retina. The foveola is devoid of the ganglion cell layer and hence remains transparent and allows transmission of the color of the choroid and the RPE. However, with the increasing age, the damaged ganglion cells are lost, and the cherry-red spot becomes less prominent. In such cases, there is consecutive optic atrophy and pallor of the optic disc due to the degeneration of the ganglion cell layer and nerve fiber layer.

Sphingolipidoses are disorders of lysosomal metabolism, which involve conjugated products of ceramide and sugar or phospholipids. Sphingolipidoses include gangliosidosis, Niemann-Pick disease, Farber disease, and metachromatic leukodystrophy.

Primary prevention

Add text here


Ruling out serious life-threatening or sight-threatening conditions is of paramount importance in a patient with a cherry-red spot at the macula, thus requiring a thorough evaluation and management of such patients.[2] It highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.


Add text here

Physical examination

Add text here


Add text here


Add text here

Clinical diagnosis

Add text here

Diagnostic procedures

Add text here

Laboratory test

Add text here

Differential diagnosis

Add text here


Add text here

General treatment

Add text here

Medical therapy

Add text here

Medical follow up

Add text here


Add text here

Surgical follow up

Add text here


Add text here


Add text here

Additional Resources

Add text here


Add text here

  1. 1.0 1.1 Suvarna J C, Hajela S A. Cherry-red spot. J Postgrad Med 2008;54:54-7
  2. 2.0 2.1 2.2 Tripathy K, Patel BC. Cherry Red Spot. [Updated 2021 Feb 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from:
  3. 3.0 3.1 3.2 General Practice Notebook
  4. 4.0 4.1 Leavitt, J. A., & Kotagal, S. (2007). The “Cherry Red” Spot. Pediatric Neurology, 37(1), 74-75 doi:10.1016/j.pediatrneurol.2007.04.011 
  5. USMLE First AID 2010 page 417